- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Kathy Oubre Previews Festival of Biologics 2022 Discussions
Kathy Oubre, MS, chief operating officer of Pontchartrain Cancer Center, previews her upcoming presentations at the Festival of Biologics conference.
Kathy Oubre, MS, chief operating officer of Pontchartrain Cancer Center, previews her upcoming presentations at the Festival of Biologics conference.
Transcript
You are going to be speaking at Terrapinn’s Festival of Biologics conference happening in March. What are you going to be discussing and what can audiences look forward to?
I will be doing a panel presentation with Sean McGowan [AmerisourceBergen]; Bhavesh Shah, RPh, BCOP; and Craig [Burton] from AAM [Association for Accessible Medicines]. We're doing the keynote on the first day, and we'll be discussing present and future considerations for the biosimilar industry. We're going to be doing a much broader kind of a 30,000-foot discussion, and in that, will talk about the current biosimilars market products and some industry milestones: where we started, where we are now, and we are going to be looking forward. We will discuss what we see coming as far as launches and what's going to be happening in the space within the next 6 months, the next year, the next 5 years. And then we'll be having probably a fairly robust discussion regarding the regulatory constraints and some policy implications around biosimilars.
Additionally, on the third day, I will be doing a panel presentation with Melody Chang, RPh, MBA, BCOP, at AON [American Oncology Network] and we'll be discussing the importance of biosimilars within the oncology landscape and kind of a crystal ball discussion of where we see biosimilars in oncology moving forward.
How Vertical Integration Drives Innovation and Access in Biosimilars
December 27th 2024Elie Bahou, PharmD, highlights how vertical integration in the biosimilar industry streamlines costs, improves supply reliability, accelerates market adoption, and enhances patient access, while emphasizing the value of collaboration, quality control, and value-based contracts for sustainable health care delivery.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
AON Saves Over $243 Million With High Biosimilar Adoption
April 22nd 2024Thanks to high biosimilar adoption rates within the community oncology setting, American Oncology Network (AON) saved upwards of $243 million between 2020 and 2023, according to a presentation at the Festival of Biologics USA conference in San Diego, California.
The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability
April 16th 2024Magnus Bodin, senior director and head of international access and policy at Biogen, presented warning signs for unsustainable biosimilar markets as well as key factors needed to create effective policies and future-proof biosimilar markets globally.
